Noa Therapeutics is a preclinical biotech company leveraging a systems biology approach to accelerate design of tailored multimodal therapeutics for complex inflammatory diseases. With discrete expertise in dermal therapeutics, Noa is advancing a first-use case in Atopic Dermatitis. Noa’s lead ID, NOA-101, simultaneously addresses three constructive targets to address persistent unmet needs to displace multiple major players within the $5.0B, 10.1% CAGR, US Market; paving the way for pipeline expansion into >$70B inflammatory disease markets.